Literature DB >> 23161162

Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine.

Lei Hu1, Sangeeta B Joshi, Mangala Roshan Liyanage, Mekala Pansalawatta, Mark R Alderson, Andrea Tate, George Robertson, Jeff Maisonneuve, David B Volkin, C Russell Middaugh.   

Abstract

Streptococcus pneumoniae is a major cause of death in children worldwide. There are more than 90 known pneumococcus serotypes that vary by geographical location. Pneumolysin is a protein toxin produced by virtually all invasive strains of S. pneumoniae and is considered an important virulence factor. Pneumolysin is immunogenic and has the potential to be a new vaccine antigen offering broad serotype-independent coverage. To develop a stable vaccine formulation, the conformational stability of a recombinant pneumolysin mutant (pneumolysoid L460D) was characterized by various techniques. Three data visualization diagrams were constructed to summarize the biophysical data of the L460D pneumolysoid; the protein is most stable in solution at pH 6-7, and loses conformational integrity above 48°C. Excipient screening assays were performed and sugars such as trehalose and sucrose stabilized the pneumolysin mutant with respect to improving thermal transition temperatures and minimizing aggregation. In addition, the protein antigen showed efficient binding to aluminum hydroxide adjuvant. The conformational stability of the L460D pneumolysoid on the surface of alhydrogel adjuvant was little affected by adsorption, either with or without excipients. These studies provide important preformulation characterization information useful for the development of a stable pneumolysin mutant-based vaccine.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161162     DOI: 10.1002/jps.23375

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

2.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

3.  A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine.

Authors:  Shyamal P Choudhari; Kirk P Pendleton; Joshua D Ramsey; Thomas G Blanchard; William D Picking
Journal:  J Pharm Sci       Date:  2013-06-21       Impact factor: 3.534

4.  Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein.

Authors:  Beth Mann; Justin Thornton; Richard Heath; Kristin R Wade; Rodney K Tweten; Geli Gao; Karim El Kasmi; John B Jordan; Diana M Mitrea; Richard Kriwacki; Jeff Maisonneuve; Mark Alderson; Elaine I Tuomanen
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

5.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

Review 6.  Current concepts in host-microbe interaction leading to pneumococcal pneumonia.

Authors:  Joshua Vernatter; Liise-anne Pirofski
Journal:  Curr Opin Infect Dis       Date:  2013-06       Impact factor: 4.915

7.  Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function.

Authors:  Armand O Brown; Beth Mann; Geli Gao; Jane S Hankins; Jessica Humann; Jonathan Giardina; Paola Faverio; Marcos I Restrepo; Ganesh V Halade; Eric M Mortensen; Merry L Lindsey; Martha Hanes; Kyle I Happel; Steve Nelson; Gregory J Bagby; Jose A Lorent; Pablo Cardinal; Rosario Granados; Andres Esteban; Claude J LeSaux; Elaine I Tuomanen; Carlos J Orihuela
Journal:  PLoS Pathog       Date:  2014-09-18       Impact factor: 6.823

8.  Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.

Authors:  Sanjeev Agarwal; Neha Sahni; John M Hickey; George A Robertson; Robert Sitrin; Stanley Cryz; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-08-07       Impact factor: 3.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.